Cerus Q2 revenue beats estimates, raises 2025 guidance
Overview
Cerus Q2 total revenue rises 19% yr/yr to $60.1 mln, beating estimates, per LSEG data
Q2 product revenue up 16% yr/yr to $52.4 mln, driven by IFC and platelet sales
Co raises full-year 2025 product revenue guidance to $200 mln - $203 mln
Outlook
Cerus raises full-year 2025 product revenue guidance to $200 mln-$203 mln
Company increases 2025 IFC revenue guidance to $16 mln-$18 mln
Cerus expects positive full-year 2025 non-GAAP adjusted EBITDA
Company anticipates continued growth in second half of 2025
Result Drivers
IFC DEMAND - Strong demand for INTERCEPT Fibrinogen Complex drove product revenue growth, with Q2 revenue rising to $5.6 mln from $2.0 mln year-ago
INT200 DEVICE - Successful launch and adoption of the new LED-based INT200 illumination device exceeded performance expectations, per CEO
GOVERNMENT CONTRACTS - Increase in government contract revenue was driven by R&D activities for the INTERCEPT RBC program and next-gen pathogen reduction technology
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $60.10 mln | $54.40 mln (4 Analysts) |
Q2 Net Income | -$5.70 mln | ||
Q2 Adjusted EBITDA | Miss | $900,000 | $2.12 mln (3 Analysts) |
Q2 Gross Margin | 55.2% | ||
Q2 Gross Profit | $29 mln | ||
Q2 Operating Expenses | $40.10 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Cerus Corp is $5.00, about 74% above its August 4 closing price of $1.30
Press Release:
